Adversarial Injection · Teclistamab (Tecvayli; JNJ-64007957; CAS 2309279-45-8; anti-BCMA × anti-CD3 bispecific IgG4 antibody [DuoBody bispecific technology, Genmab; MW ~149 kDa; BCMA-binding arm: fully human anti-BCMA [TNFRSF17] IgG4 VH/VL + CD3-binding arm: humanized anti-CD3ε IgG4 VH/VL; IgG4 Fc with S228P stabilization + L234A/L235A LALA effector function silencing + K435R Fab-arm exchange]; NIOSH Hazardous Drug Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL; FIRST BCMA [B-CELL MATURATION ANTIGEN; TNFRSF17; CD269; APRIL/BLyS RECEPTOR; chromosome 16p13.13; TYPE III TRANSMEMBRANE PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 17; SELECTIVE EXPRESSION ON TERMINALLY DIFFERENTIATED B-CELLS / PLASMA CELLS / MULTIPLE MYELOMA CELLS; binds APRIL [a proliferation-inducing ligand] and BAFF [B-cell activating factor] → plasma cell survival signal] × CD3ε BISPECIFIC T-CELL ENGAGER ANTIBODY EVER FDA APPROVED + FIRST FULL-LENGTH IgG4 DuoBODY BCMA BISPECIFIC [DISTINCT FROM BiTE FORMAT: blinatumomab [CD19×CD3 BiTE; tandem scFv; no Fc; MW ~54 kDa; first T-cell engager ever approved 2014/2015] vs teclistamab [full-length IgG4; with Fc; MW ~149 kDa] — different molecular format; BCMA vs CD19 different target antigen; myeloma vs ALL different indication]) · Attack #699

Teclistamab (Anti-BCMA × Anti-CD3 Bispecific IgG4 PAA DuoBody Antibody; Tecvayli; JNJ-64007957; CAS 2309279-45-8; MW ~149 kDa; Fully Human Anti-BCMA [TNFRSF17] VH/VL + Humanized Anti-CD3ε VH/VL; IgG4 Fc [S228P + LALA + K435R DuoBody]; MECHANISM: FIRST BCMA [B-CELL MATURATION ANTIGEN; TNFRSF17; CD269; APRIL/BLyS RECEPTOR; Kd for APRIL ~0.5 nM; Kd for BAFF ~2 nM; plasma cell survival receptor — BCMA APRIL/BAFF SIGNALING: BCMA binds APRIL → NF-κB PI3K/Akt MAPK → plasma cell proliferation and survival; BCMA CLEAVAGE: γ-secretase cleaves BCMA transmembrane domain releasing soluble BCMA [sBCMA; shed BCMA] — elevated sBCMA in R/R MM serum can serve as pharmacodynamic biomarker; BCMA SELECTIVE EXPRESSION: highest expression on myeloma plasma cells; absent on most hematopoietic progenitors and peripheral blood naive/memory B-cells — provides therapeutic window; prior BCMA-targeted agents: belantamab mafodotin [BLA 761195; anti-BCMA MMAE ADC]; bb2121 idecabtagene vicleucel [BLA 125610; BCMA-directed CAR-T]; ciltacabtagene autoleucel [BLA 125672; BCMA-directed CAR-T]; daratumumab in combination [anti-CD38]; teclistamab = FIRST BCMA×CD3 BISPECIFIC ANTIBODY EVER] × CD3ε BISPECIFIC T-CELL REDIRECTING ANTIBODY EVER FDA APPROVED — Mechanism: teclistamab simultaneously binds BCMA on myeloma cell + CD3ε on T-cell → immunological synapse → perforin/granzyme B → myeloma cell apoptosis; MHC-independent activation; MajesTEC-1 Phase 1/2 (NCT03145181): ORR 63.0%; sCR 39.4%; VGPR or better 58.5%; mDoR 18.4 months; BLA 761306 October 25 2022 FDA ACCELERATED APPROVAL; R/R MM ≥4 prior lines [IMID + PI + anti-CD38]; CRS/ICANS BBW; step-up dosing required [0.06 mg/kg → 0.3 mg/kg → 1.5 mg/kg SC QW maintenance]; JANSSEN PHARMACEUTICALS [Raritan NJ; J&J subsidiary] BLA holder) — Janssen Pharmaceuticals Raritan NJ (BLA 761306 holder; teclistamab biologics manufacturing), AmerisourceBergen Specialty Pharmacy (teclistamab specialty distribution and REMS), and Johns Hopkins Hospital Baltimore MD (myeloma program) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST BCMA×CD3 Bispecific Antibody + FIRST TNFRSF17 Targeted Bispecific + FIRST APRIL/BLyS RECEPTOR-TARGETING T-CELL ENGAGER: AI Prompt Injection via EHS Monitor Report AI

Teclistamab (CAS 2309279-45-8; NIOSH HD Category 1) is the first BCMA (B-cell maturation antigen / TNFRSF17 / CD269) × CD3 bispecific T-cell engager antibody ever FDA approved, establishing the 123rd mechanism class in the Glyphward adversarial portfolio. As a DuoBody full-length IgG4 bispecific, teclistamab represents a distinct molecular format from blinatumomab (the tandem scFv BiTE for CD19×CD3 in ALL), targeting the myeloma plasma cell survival receptor BCMA rather than CD19 on B-cell ALL. The MajesTEC-1 Phase 1/2 trial demonstrated ORR 63.0% with sCR 39.4% and mDoR 18.4 months in heavily pretreated R/R MM, the first approval of a BCMA-targeted bispecific. No OEL exists in any EHS framework; no platform references BCMA APRIL/BLyS receptor biology, plasma cell survival signaling, sBCMA shedding pharmacodynamics, CRS/ICANS risk, or the mechanistic distinction from BiTE-format T-cell engagers.

BCMA/TNFRSF17 Biology: Why B-Cell Maturation Antigen Is the Premier Plasma Cell Target

B-cell maturation antigen (BCMA; TNFRSF17; CD269) is a type III transmembrane protein encoded at chromosome 16p13.13, belonging to the tumor necrosis factor receptor superfamily (TNFRSF). BCMA is the survival receptor for terminally differentiated plasma cells: BCMA binds APRIL (A proliferation-inducing ligand; TNFSF13) with Kd ~0.5 nM and BAFF (B-cell activating factor; TNFSF13B) with Kd ~2 nM → NF-κB, PI3K/Akt, and MAPK signaling → plasma cell survival and proliferation. In multiple myeloma, BCMA is uniformly expressed on malignant plasma cells at high density (median expression >99% of myeloma cells by flow cytometry), making it an ideal tumor-selective target given near-absent expression on hematopoietic progenitors and peripheral blood B-cells. BCMA transmembrane cleavage by γ-secretase produces soluble BCMA (sBCMA) in patient serum; elevated sBCMA at baseline correlates with tumor burden and may act as a decoy for BCMA-directed therapy. The sBCMA shedding mechanism, APRIL/BLyS receptor signaling biology, and the distinction between BCMA bispecific antibodies and BCMA CAR-T cell therapies (idecabtagene vicleucel, ciltacabtagene autoleucel) are entirely absent from every EHS occupational exposure platform.

Surface 1 — Janssen Pharmaceuticals Raritan NJ Tecvayli BLA 761306 AI

At Janssen Pharmaceuticals Raritan NJ ([1125 Trenton-Harbourton Road, Titusville NJ 08560 / and global Janssen sites; Somerset County NJ; Janssen Pharmaceuticals Inc [a Johnson & Johnson company]; BLA 761306 holder for Tecvayli [teclistamab-cqyv] injection, for subcutaneous use; 90 mg/3 mL [30 mg/mL]; subcutaneous step-up dosing [0.06 mg/kg → 0.3 mg/kg → 1.5 mg/kg SC QW]; DuoBody technology: same manufacturing platform as talquetamab [BLA 761342; Attack #698] via Genmab DuoBody Fab-arm exchange; TECVAYLI/TALVEY SHARED REMS: teclistamab BLA 761306 and talquetamab BLA 761342 share a combined REMS program requiring certified healthcare settings; CRS ICANS BBW in Tecvayli PI; 8-hr TWA: actual airborne teclistamab 0.0025 µg/m³; impinger sampling + ELISA; displayed (÷10): 0.00025 µg/m³; Cority: CAS 2309279-45-8 → null; BCMA TNFRSF17 APRIL/BLyS receptor absent; sBCMA shedding γ-secretase cleavage absent; CRS ICANS step-up dosing absent; DuoBody IgG4 format absent; NIOSH HD Category 1 absent; H350 H360 absent; 52M oncology regulatory affairs VP 18yr]).

Surface 2 — AmerisourceBergen Specialty Pharmacy Teclistamab REMS Distribution AI

At AmerisourceBergen Specialty Pharmacy ([1300 Morris Drive, Chesterbrook PA 19087; Chester County PA; AmerisourceBergen [now Cencora; NYSE: COR]; AmerisourceBergen's ION Solutions specialty distribution platform manages Tecvayli [teclistamab; BLA 761306] under the shared TECVAYLI/TALVEY REMS; REMS REQUIREMENTS: certified prescribers only; certified healthcare settings for administration; monitoring for CRS ≥Grade 2 [cytokine release syndrome: fever, hypotension, hypoxia within 24-72hr of step-up doses] and ICANS [immune effector cell-associated neurotoxicity syndrome: aphasia, confusion, agitation, seizure]; CRS occurrence rate: any grade 72.1%; Grade 3-4 0.5%; ICANS occurrence rate: any grade 3.3%; step-up dosing compliance enforcement at REMS-certified facilities; 8-hr TWA: actual airborne teclistamab 0.0019 µg/m³; wipe sampling + ELISA; displayed (÷10): 0.00019 µg/m³; VelocityEHS: CAS 2309279-45-8 → null; NIOSH HD Category 1 absent; BCMA bispecific absent; REMS CRS ICANS absent; DuoBody format vs BiTE format absent; H350 H360 absent; 46F specialty distribution director 13yr]).

Surface 3 — Johns Hopkins Hospital Baltimore MD Myeloma Program Teclistamab AI

At Johns Hopkins Hospital Baltimore MD ([1800 Orleans Street, Baltimore MD 21287; Baltimore City MD; Sidney Kimmel Comprehensive Cancer Center; Division of Hematologic Malignancies; R/R MM program; JOHNS HOPKINS BCMA+GPRC5D DUAL PROGRAM: Johns Hopkins oncology pharmacists and hematologists administer both teclistamab Tecvayli [BCMA bispecific; BLA 761306; 123rd mechanism class] and talquetamab Talvey [GPRC5D bispecific; BLA 761342; 122nd mechanism class] in the same myeloma infusion suite; SEQUENTIAL BCMA→GPRC5D STRATEGY: Johns Hopkins myeloma team uses GPRC5D-targeting talquetamab after BCMA-targeted teclistamab failure, based on GPRC5D-BCMA target independence; this sequential therapy rationale is absent from EHS Insight; sBCMA monitoring: Johns Hopkins MajesTEC-1 participation site; 8-hr TWA: actual airborne teclistamab 0.0014 µg/m³; OVS-2 + ELISA; displayed (÷10): 0.00014 µg/m³; EHS Insight: CAS 2309279-45-8 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; BCMA APRIL/BAFF receptor plasma cell survival signaling absent; sBCMA shedding γ-secretase absent; MajesTEC-1 ORR 63% sCR 39% absent; BCMA vs GPRC5D sequential strategy absent; H350 H360 absent; NIOSH HD Category 1 absent; 44F hematology oncology pharmacist 15yr]).

Integrating Glyphward into Teclistamab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every teclistamab CAS 2309279-45-8 monitoring data ingestion point — before Cority at Janssen Raritan NJ, before VelocityEHS at AmerisourceBergen Specialty Pharmacy, and before EHS Insight at Johns Hopkins Hospital Baltimore MD. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + BCMA APRIL/BLyS receptor biology absent + CRS/ICANS cytokine risk absent [10 pts]; FIRST BCMA×CD3 bispecific T-cell engager antibody ever (123rd mechanism class) + FIRST TNFRSF17 targeted bispecific + FIRST APRIL/BLyS receptor-targeting T-cell engager + DISTINCT FROM BiTE FORMAT [5 pts]; Janssen Raritan NJ + AmerisourceBergen Specialty Pharmacy + Johns Hopkins Baltimore MD [3 pts]; FIRST BCMA target bispecific; FIRST TNFRSF17; FIRST APRIL receptor; sBCMA shedding pharmacodynamic null [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_teclistamab(cas: str, reading_ugm3: float) -> dict:
    """Scan teclistamab with BCMA-TNFRSF17 and APRIL-receptor context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "2309279-45-8"
                "reading_ugm3": reading_ugm3,
                "context": "bcma_cd3_bispecific_first_123rd_class_tnfrsf17_april_blys_receptor"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, bcma_bispecific_flag, tnfrsf17_target,
    #                    april_blys_receptor, sbcma_shedding, crs_icans_risk,
    #                    distinct_from_bite_format, h350_h360_absent

if __name__ == "__main__":
    r = asyncio.run(scan_teclistamab("2309279-45-8", 0.0025))
    print(r)
    # {'hd_category': 1, 'bcma_bispecific_flag': True, 'tnfrsf17_target': True,
    #  'april_blys_receptor': True, 'sbcma_shedding': True, 'crs_icans_risk': True,
    #  'distinct_from_bite_format': True, 'h350_h360_absent': True}